These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 18083554

  • 1. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
    Deak HL, Newcomb JR, Nunes JJ, Boucher C, Cheng AC, DiMauro EF, Epstein LF, Gallant P, Hodous BL, Huang X, Lee JH, Patel VF, Schneider S, Turci SM, Zhu X.
    Bioorg Med Chem Lett; 2008 Feb 01; 18(3):1172-6. PubMed ID: 18083554
    [Abstract] [Full Text] [Related]

  • 2. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Chai L, Chaffee SC, Deak HL, Epstein LF, Faust T, Gallant P, Gore A, Gu Y, Henkle B, Hsieh F, Huang X, Kim JL, Lee JH, Martin MW, McGowan DC, Metz D, Mohn D, Morgenstern KA, Oliveira-dos-Santos A, Patel VF, Powers D, Rose PE, Schneider S, Tomlinson SA, Tudor YY, Turci SM, Welcher AA, Zhao H, Zhu L, Zhu X.
    J Med Chem; 2008 Mar 27; 51(6):1681-94. PubMed ID: 18321037
    [Abstract] [Full Text] [Related]

  • 3. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
    Martin MW, Newcomb J, Nunes JJ, McGowan DC, Armistead DM, Boucher C, Buchanan JL, Buckner W, Chai L, Elbaum D, Epstein LF, Faust T, Flynn S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Lee JH, Metz D, Middleton S, Mohn D, Morgenstern K, Morrison MJ, Novak PM, Oliveira-dos-Santos A, Powers D, Rose P, Schneider S, Sell S, Tudor Y, Turci SM, Welcher AA, White RD, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Amouzegh P, Ermann M, Jenkins J, Johnston D, Napier S, Power E.
    J Med Chem; 2006 Aug 10; 49(16):4981-91. PubMed ID: 16884310
    [Abstract] [Full Text] [Related]

  • 4. Pyrrole derivatives as potent inhibitors of lymphocyte-specific kinase: Structure, synthesis, and SAR.
    Takayama T, Umemiya H, Amada H, Yabuuchi T, Shiozawa F, Katakai H, Takaoka A, Yamaguchi A, Endo M, Sato M.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):108-11. PubMed ID: 19945869
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW, Newcomb J, Nunes JJ, Boucher C, Chai L, Epstein LF, Faust T, Flores S, Gallant P, Gore A, Gu Y, Hsieh F, Huang X, Kim JL, Middleton S, Morgenstern K, Oliveira-dos-Santos A, Patel VF, Powers D, Rose P, Tudor Y, Turci SM, Welcher AA, Zack D, Zhao H, Zhu L, Zhu X, Ghiron C, Ermann M, Johnston D, Saluste CG.
    J Med Chem; 2008 Mar 27; 51(6):1637-48. PubMed ID: 18278858
    [Abstract] [Full Text] [Related]

  • 7. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M, VanRens JC, Laufersweiler MJ, Brugel TA, Maier J, Golebiowski A, De B, Easwaran V, Hsieh LC, Walter RL, Mekel MJ, Evdokimov A, Janusz MJ.
    Bioorg Med Chem Lett; 2006 Dec 01; 16(23):5973-7. PubMed ID: 16997556
    [Abstract] [Full Text] [Related]

  • 8. Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formation.
    Walker DP, Bi FC, Kalgutkar AS, Bauman JN, Zhao SX, Soglia JR, Aspnes GE, Kung DW, Klug-McLeod J, Zawistoski MP, McGlynn MA, Oliver R, Dunn M, Li JC, Richter DT, Cooper BA, Kath JC, Hulford CA, Autry CL, Luzzio MJ, Ung EJ, Roberts WG, Bonnette PC, Buckbinder L, Mistry A, Griffor MC, Han S, Guzman-Perez A.
    Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6071-7. PubMed ID: 18951788
    [Abstract] [Full Text] [Related]

  • 9. Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Wang H, Ruan Z, Li JJ, Simpkins LM, Smirk RA, Wu SC, Hutchins RD, Nirschl DS, Van Kirk K, Cooper CB, Sutton JC, Ma Z, Golla R, Seethala R, Salyan ME, Nayeem A, Krystek SR, Sheriff S, Camac DM, Morin PE, Carpenter B, Robl JA, Zahler R, Gordon DA, Hamann LG.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3168-72. PubMed ID: 18485702
    [Abstract] [Full Text] [Related]

  • 10. Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR.
    Takayama T, Umemiya H, Amada H, Yabuuchi T, Koami T, Shiozawa F, Oka Y, Takaoka A, Yamaguchi A, Endo M, Sato M.
    Bioorg Med Chem Lett; 2010 Jan 01; 20(1):112-6. PubMed ID: 19945867
    [Abstract] [Full Text] [Related]

  • 11. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
    Chen P, Norris D, Das J, Spergel SH, Wityak J, Leith L, Zhao R, Chen BC, Pitt S, Pang S, Shen DR, Zhang R, De Fex HF, Doweyko AM, McIntyre KW, Shuster DJ, Behnia K, Schieven GL, Barrish JC.
    Bioorg Med Chem Lett; 2004 Dec 20; 14(24):6061-6. PubMed ID: 15546730
    [Abstract] [Full Text] [Related]

  • 12. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G, Ren P, Gray NS, Sim T, Liu Y, Wang X, Che J, Tian SS, Sandberg ML, Spalding TA, Romeo R, Iskandar M, Chow D, Martin Seidel H, Karanewsky DS, He Y.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5618-21. PubMed ID: 18793846
    [Abstract] [Full Text] [Related]

  • 13. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M, Vanrens JC, Brugel TA, Maier J, Laufersweiler MJ, Golebiowski A, De B, Easwaran V, Hsieh LC, Rosegen J, Berberich S, Suchanek E, Janusz MJ.
    Bioorg Med Chem Lett; 2006 Aug 15; 16(16):4257-61. PubMed ID: 16757169
    [Abstract] [Full Text] [Related]

  • 14. Disubstituted pyrimidines as Lck inhibitors.
    Hunt JA, Beresis RT, Goulet JL, Holmes MA, Hong XJ, Kovacs E, Mills SG, Ruzek RD, Wong F, Hermes JD, Park YW, Salowe SP, Sonatore LM, Wu L, Woods A, Zaller DM, Sinclair PJ.
    Bioorg Med Chem Lett; 2009 Sep 15; 19(18):5440-3. PubMed ID: 19674899
    [Abstract] [Full Text] [Related]

  • 15. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.
    DiMauro EF, Newcomb J, Nunes JJ, Bemis JE, Boucher C, Buchanan JL, Buckner WH, Cheng A, Faust T, Hsieh F, Huang X, Lee JH, Marshall TL, Martin MW, McGowan DC, Schneider S, Turci SM, White RD, Zhu X.
    Bioorg Med Chem Lett; 2007 Apr 15; 17(8):2305-9. PubMed ID: 17280833
    [Abstract] [Full Text] [Related]

  • 16. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone.
    Kung PP, Funk L, Meng J, Collins M, Zhou JZ, Johnson MC, Ekker A, Wang J, Mehta P, Yin MJ, Rodgers C, Davies JF, Bayman E, Smeal T, Maegley KA, Gehring MR.
    Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6273-8. PubMed ID: 18929486
    [Abstract] [Full Text] [Related]

  • 17. Rapid development of piperidine carboxamides as potent and selective anaplastic lymphoma kinase inhibitors.
    Bryan MC, Whittington DA, Doherty EM, Falsey JR, Cheng AC, Emkey R, Brake RL, Lewis RT.
    J Med Chem; 2012 Feb 23; 55(4):1698-705. PubMed ID: 22263917
    [Abstract] [Full Text] [Related]

  • 18. Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.
    Martin MW, Newcomb J, Nunes JJ, Bemis JE, McGowan DC, White RD, Buchanan JL, DiMauro EF, Boucher C, Faust T, Hsieh F, Huang X, Lee JH, Schneider S, Turci SM, Zhu X.
    Bioorg Med Chem Lett; 2007 Apr 15; 17(8):2299-304. PubMed ID: 17276681
    [Abstract] [Full Text] [Related]

  • 19. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection.
    Burchat A, Borhani DW, Calderwood DJ, Hirst GC, Li B, Stachlewitz RF.
    Bioorg Med Chem Lett; 2006 Jan 01; 16(1):118-22. PubMed ID: 16216497
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and structure based optimization of novel Akt inhibitors.
    Lippa B, Pan G, Corbett M, Li C, Kauffman GS, Pandit J, Robinson S, Wei L, Kozina E, Marr ES, Borzillo G, Knauth E, Barbacci-Tobin EG, Vincent P, Troutman M, Baker D, Rajamohan F, Kakar S, Clark T, Morris J.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3359-63. PubMed ID: 18456494
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.